연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
2155. Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma.
Seo JS#1,2,3,4, Lee JW#2,3, Kim A#2,3, Shin JY#2,4, Jung YJ5, Lee SB5, Kim YH5, Park S6, Lee HJ6, Park IK6, Kang CH6, Yun JY2,4, Kim J2,4, Kim YT7,5,6.
Cancer Immunol Res. 2018 Jul;6(7):848-859. doi: 10.1158/2326-6066.CIR-17-0453. Epub 2018 May 2.
Link
2154. A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
Jang BS1, Kim IA2.
Radiother Oncol. 2018 Aug;128(2):245-253. doi: 10.1016/j.radonc.2018.05.003. Epub 2018 May 18.
Link
2153. Prediction of Pseudoprogression versus Progression using Machine Learning Algorithm in Glioblastoma.
Jang BS1, Jeon SH1, Kim IH1,2, Kim IA3,4.
Sci Rep. 2018 Aug 21;8(1):12516. doi: 10.1038/s41598-018-31007-2.
Link
2152. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation.
Shin J1, Dan K2, Han D2, Kim JW3, Kim KK4, Koh Y1, Shin DY1, Hong J1, Yoon SS1, Park S5, Song SH6, Kim I7.
Blood Cells Mol Dis. 2019 Feb;74:5-12. doi: 10.1016/j.bcmd.2018.10.001. Epub 2018 Oct 4.
Link
2151. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Shin J1, Koh Y1, Yoon SH2, Cho JY2, Kim DY3, Lee KH3, Kim HJ4, Ahn JS4, Kim YK4, Park J5, Sohn SK6, Moon JH6, Lee YJ6, Yoon S7, Lee JO8, Cheong JW9, Kim KH10, Kim SH11, Kim HG12, Kim H13, Nam SH14, Do YR15, Park SG16, Park SK17, Bae SH18, Song HH19, Shin DY20, Oh D21, Kim MK22, Jung CW23, Park S1, Kim I1.
Cancer Med. 2018 May;7(5):1814-1823. doi: 10.1002/cam4.1450. Epub 2018 Mar 25.
Link
2150. Temporal trajectory of quality of life and its predictors in recipients of hematopoietic stem cell transplantation.
Kim R1, Son KL2, Lee KM3,4, Choi Y1, Hong J1, Shin DY1, Koh Y1, Hahm BJ5, Kim I6,7.
Ann Hematol. 2018 Aug;97(8):1407-1415. doi: 10.1007/s00277-018-3319-4. Epub 2018 Apr 3.
Link
2149. Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma.
Jeon SH, Park S-H, Kim JW, Park C-K, Paek SH, Kim IH
J Neuro-Oncol 2018 May ;137(3):567-573
Link
2148. Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups
Chun SJ, Park SH, Park CK, Kim JW, Kim TM, Choi SH, Lee ST, Kim IH..
Radiother Oncol. August 2018;128(2):254-259.
Link
2147. Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.
Wee CW, Kim IH, Park CK, Kim JW, Dho YS, Ohka F, Aoki K, Motomura K, Natsume A, Kim N, Suh CO, Chang JH, Kim SH, Cho WK, Lim DH, Nam DH, Choi JW, Kim IA, Kim CY, Oh YT, Cho O, Chung WK, Kim SH, Kim E.
Radiother Oncol. 2018 Nov;129(2):3437-351.
Link
2146. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
Kim S1, Kim TM1,2, Kim DW1,2, Kim S1, Kim M1, Ahn YO1, Keam B1,2, Heo DS1,2.
Cancer Res Treat. 2018 Oct 10. doi: 10.4143/crt.2018.052. [Epub ahead of print]
Link